Can't find Leuprolide? Learn about Goserelin, Triptorelin, Degarelix, Relugolix, and other alternatives that may work for your condition.
If you've been trying to fill your Leuprolide prescription and keep hitting dead ends, you're not alone. The ongoing Leuprolide shortage has left many patients scrambling — and wondering whether there's something else that could work.
The answer, in most cases, is yes. There are several medications in the same drug class or with similar effects that your doctor may consider. But switching medications isn't something to do on your own — it requires a conversation with your prescriber about your specific condition, treatment history, and what's available.
Here's what you need to know about the alternatives.
Leuprolide (brand names Lupron Depot, Eligard, Fensolvi, Camcevi) is a gonadotropin-releasing hormone (GnRH) agonist. It works by continuously stimulating GnRH receptors in the pituitary gland, which — counterintuitively — causes the pituitary to stop producing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) after an initial surge.
The result: testosterone drops to castrate levels in men, and estrogen drops to postmenopausal levels in women. This makes it effective for hormone-sensitive conditions like prostate cancer, endometriosis, uterine fibroids, and central precocious puberty.
For a full overview, see our guide on what Leuprolide is and how it's used.
Drug class: GnRH agonist
How it's given: Subcutaneous implant injected into the abdominal wall every 1 month (3.6mg) or every 3 months (10.8mg).
Approved for: Advanced prostate cancer, breast cancer, endometriosis, and endometrial thinning before surgery.
Key differences from Leuprolide: Goserelin uses a small solid implant (about the size of a grain of rice) rather than a liquid depot injection. It's administered subcutaneously rather than intramuscularly. Some studies suggest Goserelin may be slightly better at maintaining consistently low testosterone levels compared to Leuprolide.
Availability: Goserelin (Zoladex) is manufactured by AstraZeneca and has generally maintained more stable supply than Lupron Depot. It may be a good option if Leuprolide is unavailable.
Drug class: GnRH agonist
How it's given: Intramuscular injection every 1 month (3.75mg), every 3 months (11.25mg), or every 6 months (22.5mg). Triptodur is a 6-month formulation specifically for central precocious puberty.
Approved for: Advanced prostate cancer and central precocious puberty.
Key differences from Leuprolide: Triptorelin works through the same mechanism as Leuprolide and is given as a similar depot injection. It's considered clinically equivalent for prostate cancer treatment. Triptodur offers a 6-month option for pediatric patients with CPP, which can be an important alternative when Lupron Depot-Ped is unavailable.
Availability: Manufactured by Verity Pharmaceuticals (Trelstar) and Arbor Pharmaceuticals (Triptodur), these products have different supply chains than Lupron Depot, so they may be available when Lupron is not.
Drug class: GnRH antagonist (not an agonist)
How it's given: Subcutaneous injection. Initial dose: two 120mg injections, then 80mg monthly.
Approved for: Advanced prostate cancer.
Key differences from Leuprolide: This is an important distinction — Degarelix is a GnRH antagonist, not an agonist. It blocks GnRH receptors directly rather than overstimulating them. The major clinical advantage is that Degarelix does not cause the initial testosterone flare that occurs with GnRH agonists like Leuprolide. This makes it particularly useful for patients with symptomatic metastatic disease where a flare could be dangerous (spinal cord compression, urinary obstruction).
Limitation: Only approved for prostate cancer, and requires monthly injections (no 3-month or 6-month option). The injection can cause injection-site reactions more frequently than Leuprolide.
Drug class: GnRH antagonist (oral)
How it's taken: One tablet by mouth daily (120mg after a 360mg loading dose on day 1).
Approved for: Advanced prostate cancer.
Key differences from Leuprolide: Relugolix is the first and only oral GnRH antagonist approved for prostate cancer. No injections required. Like Degarelix, it does not cause a testosterone flare. In clinical trials, it achieved castrate testosterone levels faster than Leuprolide and showed a lower rate of cardiovascular events. Testosterone recovery after stopping treatment is also faster.
Limitation: Currently only FDA-approved for prostate cancer. Must be taken daily (compared to monthly or less frequent injections with depot formulations). May interact with certain medications including P-glycoprotein inhibitors.
While all of these medications work to suppress sex hormones, they are not interchangeable without medical supervision. Doses, administration routes, monitoring requirements, and insurance coverage vary. Your doctor needs to evaluate:
If you can't find Leuprolide, don't panic — but don't delay either. Talk to your doctor about the alternatives listed above, and use Medfinder to check whether Leuprolide or its alternatives are in stock near you. The most important thing is that you don't go without treatment.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
